News Sentiment

BNGO sentiment intelligence

Bionano Genomics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 1.20 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

86/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+4.3% over one week, +3.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Precision Trading with Bionano Genomics Inc. (BNGO) Risk Zones

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 86/100 classification
One-week reaction 4.3% Price confirming higher
Trend fit Trend inactive 3.4% over four weeks
Fair value -97.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 39
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
TradingKey 7
TradingView 6
GlobeNewswire 4
Investing.com 4
The Globe and Mail 3
Market source 3
The Manila Times 2

Event Lens

What the news is about

Classified themes
Market update 44
Earnings 9
Analyst action 4
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
The Globe and Mail Direct company coverage

BioNano Genomics Announces Resignation of Chief Medical Officer

BioNano Genomics announced the resignation of its Chief Medical Officer, Alka Chaubey, Ph.D., effective July 5, 2026. This departure may lead to adjustments in the company's clinical strategy. Analysts currently rate BNGO stock as a Buy with a $4.00 price target, though Spark, Ti

Tone
Negative 39/100
Event
Analyst action
Published
07 Jun 2026 13:09
Source
The Globe and Mail
Stock Titan Direct company coverage

Bionano Genomics (NASDAQ: BNGO) Chief Medical Officer to step down

Bionano Genomics, Inc. announced that its Chief Medical Officer, Alka Chaubey, Ph.D., submitted her resignation on June 2, 2026, which will become effective on July 5, 2026. The company, traded on Nasdaq under BNGO, reported this material event in an 8-K filing. Albert A. Luderer

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 19:41
Source
Stock Titan
Investing.com Direct company coverage

Bionano appoints board chairman as interim CEO

Bionano Genomics, Inc. (NASDAQ:BNGO) has appointed Al Luderer, its current board chairman, as interim president and CEO, effective Monday. Luderer, who has extensive biotechnology experience, will continue as chairman while Chris Twomey becomes Lead Independent Director. This lea

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 11:09
Source
Investing.com
Stock Titan Direct company coverage

Bionano Genomics (BNGO) counsel has 24 shares withheld for RSU taxes

Bionano Genomics' General Counsel, Jonathan V. Dixon, recently had 24 common shares withheld by the company to cover tax obligations related to a vested Restricted Stock Unit (RSU) award. This routine tax-withholding disposition, occurring on June 3, 2026, was priced at $1.30 per

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 10:39
Source
Stock Titan
Stock Titan Direct company coverage

Bionano Genomics (BNGO) COO records 27-share tax withholding event

Bionano Genomics Chief Operating Officer Mark Oldakowski reported a tax-related disposition of 27 shares of common stock. These shares, valued at $1.30 each, were withheld by the company on June 3, 2026, to cover tax obligations arising from a vested restricted stock unit (RSU) a

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

Bionano Genomics (BNGO) CMO has 24 vested shares withheld for tax obligations

Bionano Genomics' Chief Medical Officer, Alka Chaubey, had 24 shares of common stock withheld by the company to cover tax obligations on vested restricted stock units (RSUs). The shares, valued at $1.30 each, were part of an RSU award granted on June 3, 2024, which vested on June

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 01:10
Source
Stock Titan
Stock Titan Direct company coverage

Bionano Genomics (BNGO) officer reports 7-share tax withholding

Bionano Genomics' Principal Accounting Officer, Mark Adamchak, reported a routine tax-related share withholding of 7 common stock shares on June 3, 2026. The shares, valued at $1.30 each, were withheld by the company to cover tax obligations when an RSU award vested. Following th

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 01:10
Source
Stock Titan
Zacks Investment Research Direct company coverage

Bionano Genomics (BNGO)

Tone
Neutral 50/100
Event
Market update
Published
26 Sep 2018 10:05
Source
Zacks Investment Research